RxDoctor Payments Data

John Gardner, MD

Interventional Cardiology · Germantown, TNNPI 1184883852

Payments from drug & device makers

$9,622in general payments, 2019–2025

Across 511 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Abbott$2K
  • Novartis$1K
  • Medtronic$1K
  • Edwards Lifesciences$729
  • Merck$339
  • plus $3K from 35 others

What the payments were for

  • Travel & lodging$1,81719%
  • Food & beverage$7,80481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,622 in reported general payments places this provider in the 50th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$401,311
Medicare patients
1,391
Services billed
4,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$312,354
Repatha SureclickEvolocumab124$78,786
EntrestoSacubitril/Valsartan56$71,229
XareltoRivaroxaban46$63,790
JardianceEmpagliflozin44$41,722
FarxigaDapagliflozin Propanediol23$23,472
BrilintaTicagrelor32$20,544
Rosuvastatin Calcium369$4,969
Ezetimibe162$4,913
Atorvastatin Calcium316$3,409
Nebivolol Hcl47$2,943
Metoprolol Succinate170$2,436
Potassium Chloride119$2,219
Losartan Potassium189$2,125
ClopidogrelClopidogrel Bisulfate172$2,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$310$312,354311 claims
NovartisEntresto$1,272$71,22956 claims
Johnson & JohnsonXarelto$301$63,79046 claims
AstraZenecaFarxiga, Brilinta$223$44,01655 claims
Boehringer IngelheimJardiance$128$41,72244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →